| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | p50; KBF1; p105; EBP-1; NF-kB1; NFKB-p50; NFkappaB; NF-kappaB; NFKB-p105; NF-kappa-B |
| Entrez GeneID | 4790; |
| WB Predicted band size | 105kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein corresponding to residues near the C terminal of human nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于NFKB1抗体的参考文献摘要概括：
1. **文献名称**：*NF-κB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages*
**作者**：Chen F, et al.
**摘要**：该研究使用NFKB1特异性抗体进行染色质免疫沉淀(ChIP)和Western blot分析，发现p50同源二聚体通过抑制促炎细胞因子(如TNF-α)并促进抗炎因子(如IL-10)的表达，在巨噬细胞中发挥免疫调节作用。
2. **文献名称**：*Antibody-specific detection of NF-κB p50 and p65 subunits in inflammatory tissue*
**作者**：Kaltschmidt B, et al.
**摘要**：研究验证了多种商业NFKB1(p50)和RelA(p65)抗体的特异性，通过免疫组化和免疫荧光技术，揭示了慢性炎症组织中NF-κB亚基的核转位模式，为抗体在病理模型中的应用提供了实验依据。
3. **文献名称**：*Targeting NF-κB p50 in melanoma: Antibody-based inhibition reduces tumor growth and metastasis*
**作者**：Luo JL, et al.
**摘要**：通过抗NFKB1 p50单克隆抗体阻断其功能，显著抑制小鼠黑色素瘤模型的肿瘤生长和转移，表明靶向p50的抗体治疗在癌症干预中的潜在价值。
4. **文献名称**：*NFKB1 polymorphisms and antibody-mediated autoimmune responses: A case-control study*
**作者**：Li H, et al.
**摘要**：研究利用ELISA和流式细胞术结合NFKB1抗体，发现特定NFKB1基因多态性与系统性红斑狼疮患者自身抗体水平升高相关，提示其参与自身免疫疾病的分子机制。
这些文献涵盖了NFKB1抗体在机制研究、实验验证、治疗应用及疾病关联中的关键作用。
The NFKB1 antibody is a crucial tool in studying the NF-κB signaling pathway, which regulates diverse biological processes including immune responses, inflammation, cell survival, and proliferation. NFKB1 (Nuclear Factor Kappa B Subunit 1) encodes the p105 precursor protein, which is processed into the active p50 subunit. This subunit forms homodimers or heterodimers (e.g., with RelA/p65) to bind DNA and regulate target gene expression. Dysregulation of NFKB1 is linked to chronic inflammation, autoimmune diseases, and cancers.
NFKB1 antibodies are designed to detect and quantify the p105/p50 proteins in various experimental setups, such as Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. They help researchers investigate NF-κB activation mechanisms, subcellular localization (e.g., cytoplasmic retention vs. nuclear translocation), and interactions with inhibitory proteins like IκB. Specificity varies among antibodies; some recognize full-length p105. others target the processed p50 or phosphorylated forms.
These antibodies are vital in both basic research and clinical applications. For instance, they aid in profiling NF-κB activity in cancer models, evaluating drug candidates that modulate the pathway, or studying inflammatory diseases like rheumatoid arthritis. Validation across species (human, mouse, rat) and sample types (tissues, cell lysates) ensures broad utility. However, careful optimization of experimental conditions is required due to cross-reactivity risks or isoform complexity. Overall, NFKB1 antibodies remain indispensable for dissecting NF-κB biology and its therapeutic implications.
×
